estradiol/norethindrone acetate (E2/NETA)

DRUG2 trials

Sponsors

AbbVie (prior sponsor, Abbott), AbbVie

Conditions

EndometriosisHeavy Uterine BleedingUterine Fibroids

Phase 2

Safety and Efficacy of Elagolix in Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids

CompletedNCT01441635

AbbVie (prior sponsor, Abbott)Heavy Uterine Bleeding, Uterine Fibroids

Start: 2011-09-08End: 2014-05-17Updated: 2021-07-13

Phase 3

A Study to Evaluate Safety and Efficacy of Elagolix in Participants With Endometriosis With Associated Moderate to Severe Pain

TerminatedNCT03343067

AbbVieEndometriosis

Start: 2017-12-27End: 2018-10-23Updated: 2019-11-27

Related Papers

Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study

Fertility and Sterility2017-06-0276 citations

Validation of the 4 week recall version of the Uterine Fibroid Symptom and Health-related Quality of Life (UFS-QOL) Questionnaire

Current Medical Research and Opinion2016-10-1324 citations